Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
69.6M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
7.47M
-
Shares change
-
0
-
Total reported value, excl. options
-
$77.5M
-
Price
-
$9.75
Significant Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) as of Q4 2023
2 filings reported holding PHAT - Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q4 2023.
Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.47M shares
of 69.6M outstanding shares and own 10.74% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (10.1M shares), TAKEDA PHARMACEUTICAL CO LTD (7.46M shares), Medicxi Ventures Management (Jersey) Ltd (3.76M shares), Carlyle Group Inc. (3.5M shares), Invesco Ltd. (3.17M shares), BlackRock Inc. (2.68M shares), Ensign Peak Advisors, Inc (2.28M shares), NEA Management Company, LLC (1.96M shares), VANGUARD GROUP INC (1.96M shares), and Avidity Partners Management LP (1.72M shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.